CGNI
Cardiogeni Plc
Access
ISIN
GB00BTBLFC12
Bid
20.00
Mid
25.00
Ask
30.00
Key Information
- Price Change
- 0.00%
- Year High
- 60.00
- Year Low
- 25.00
- Last Trade
- 5 Feb 25
- Market Cap
- £21.34M
- Par
- 0.01
- Bid
- 20.00
- Mid Price
- 25.00
- Ask
- 30.00
- Instrument Type
- Ordinary Shares
- MIFID Status
- MTF
- Tradable Securities
- 85.35M
- Sector
- Healthcare
Prices in GBX except for Market Cap in GBP
About Cardiogeni Plc
Founded by Nobel Laureate, Professor Sir Martin Evans, the Cardiogeni Group is developing a new class of life-saving cellular medicines. The Group’s platform technology enables the creation of unique (living) cells that are engineered with a therapeutic function. The Group’s lead product, CLXR-001, is a patented engineered cellular medicine to treat heart failure patients which is administered during coronary artery bypass grafting surgery.The Group’s novel technology was developed in-house by Professor Sir Martin Evans and is protected by a portfolio of ~100 international patents and trademarks. CLXR-001 targets heart failure and consists of a novel allogeneic (off-the-shelf) cell type, iMP cells, engineered for cardiac regeneration, which will affect 1 in 4 people in their lifetime and is not reversible or curable. This technology is expected to regenerate the damaged heart tissue restoring heart function and improving life expectancy and quality of life. CLXR-001 has successfully completed an EU Phase II clinical trial in which patients showed a statistically significant (P<0.05) improvement in all parameters including heart function, reduction in heart scarring and an improvement in quality of life.
Today's Trading
Volume | Number Trades | Value Trades (GBP ) |
---|---|---|
0 | 0 | 0.00 |
Latest Trades
Date | Volume | Price (GBX) | Value (GBP) |
---|---|---|---|
05 Feb 25 08:02 | 220 | 41.00 | 90.20 |
04 Feb 25 10:56 | 20,000 | 25.00 | 5,000.00 |
03 Feb 25 11:34 | 150 | 66.00 | 99.00 |
03 Feb 25 10:18 | 150 | 66.00 | 99.00 |
Latest Announcements & Notices
Date | Title |
---|---|
No announcements or notices |
Address
Registered Address
Celixir House Stratford-Upon-Avon Business & Technology Park, Innovation Way, Stratford-Upon-Avon, Warwickshire, CV37 7GZ, United Kingdominfo@cardiogeniplc.com
Phone
+44(0) 1789 576047
Contacts
Corporate Adviser
First Sentinel Corporate Finance, 72 Charlotte Street, London , W1T 4QQ, United KingdomRegistrar
Neville Registrars Limited , Neville House,Steelpark Road, Halesowen, West Midlands, B62 8HD, United Kingdom